Gland Pharma shares picked up as a large block deal with almost 4.5% of the company’s equity worth about ₹2,121 crore or so came to the market.
The large trade has also attracted the eye of investors who believe that Fosun Pharma could be the seller.
The deal involved about 75 lakh Gland Pharma shares and the average price was about ₹2,828 per share.
While no information was available about buyers, the sale has led to speculation about a reduction in the promoter’s stake.
Fosun Pharma Likely Behind the Stake Sale
Fosun Pharma Industrial, the company’s promoter of Gland Pharma, had been looking to sell a part of its share through a block deal.
The company held approximately 51.77% of Gland Pharma as of June 30, 2026, making it the pharmaceutical firm’s largest shareholder.
For about ₹2,279.5 crore, Fosun Pharma could sell around 5% of its holding at a floor price of ₹2,763 per share.
So investors are now watching closely in the deal and wondering whether the transaction is a part of Fosun Pharma’s previously indicated stake-reduction strategy.
Gland Pharma Posts Strong Quarterly Performance
The block deal comes at the time when Gland Pharma has been reporting healthy financial performance.
In the first quarter of FY27, the pharmaceutical company reported a 47% year-on-year increase in consolidated net profit to ₹317 crore compared to ₹216 crore in the previous year.
And the company’s revenue from operations also increased by about 20% to ₹1,800 crore, indicating continued growth across all business operations.
Gland Pharma’s contract development and manufacturing organisation (CDMO) business remained an important contributor during the quarter.
It accounted for about half of the company’s revenue and grew 20% year-on-year.
The company also increased the investment in research and development with R&D expenditure of about ₹77.2 crore in the quarter. Adjusted EBITDA grew 37% year-on-year.
Investors Watch Promoter Holding
Big block deals have also attracted attention as they can lead to more trading activity and influence short-term investor sentiment.
But a promoter reducing its stake does not automatically signal a negative outlook for the company.
Investors will also be looking forward to forthcoming exchange disclosures to gain a clearer picture of how the deal went down and the exact change of Fosun Pharma’s share of the company.
Gland Pharma has also recently reported a favourable outcome from a US Food and Drug Administration inspection at its facilities in Visakhapatnam, as the inspection concluded without Form 483 observations.
With the recent block deal and the promoter’s possible stake reduction in focus, Gland Pharma should be on the radar of stock market investors and pharmaceutical sector observers.
Comments
Please to leave a comment on this article.